The oncofetal H19 RNA connection: Hypoxia, p53 and cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1803, Issue 4, 2010, Pages 443-451

  Matouk, Imad J ^a,b   Mezan, Shaul ^a   Mizrahi, Aya ^a   Ohana, Patricia ^a   Abu lail, Rasha ^a   Fellig, Yakov ^a   deGroot, Nathan ^a   Galun, Eithan ^b   Hochberg, Abraham ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cell viability; H19 non coding RNA; Hypoxia; Hypoxia inducible factor alpha; P53 tumor suppressor

Indexed keywords

PROTEIN P53; RNA H19;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ANOXIA; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA, UNTRANSLATED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950370221     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2010.01.010     Document Type: Article

References (35)

1. Rankin E.B., Giaccia A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15:678-685.
2. Matouk I.J., deGroot N., Mezan S., Ayesh S., Abu-Lail R., Hochberg A., Galun E. The H19 non-coding RNA is essential for human tumor growth. PloS ONE 2007, 2:e845.
3. Brannan C.I., Dees E.C., Ingram R.S., Tilghman S.M. The product of the H19 gene may function as an RNA. Mol. Cell. Biol. 1990, 10:28-36.
4. Leibovitch M.P., Nguyen V.C., Gross M.S., Solhonne B., Leibovitch S.A., Bernheim A. The human ASM (adult skeletal muscle) gene: expression and chromosomal assignment to 11p15. Biochem. Biophys. Res. Commun. 1991, 180:1241-1250.
5. Hao Y., Crenshaw T., Moulton T., Newcomb E., Tycko B. Tumor-suppressor activity of H19 RNA. Nature 1993, 365:764-767.
6. Poirier F., Chan C.T., Timmons P.M., Robertson E.J., Evans M.J., Rigby P.W. The murine H19 gene is activated during embryonic stem cell differentiation in vitro and at the time of implantation in the developing embryo. Development 1991, 113:1105-1114.
7. DeBaun M.R., Niemitz E.L., McNeil D.E., Brandenburg S.A., Lee M.P., Feinberg A.P. Epigenetic alternations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am. J. Hum. Genet. 2002, 70:604-611.
8. Moulton T., Crenshaw T., Hao Y., Moosikasuwan J., Lin N., Dembitzer F., Hensle T., Weiss L., McMorrow L., Loew T., Kraus W., Gerald W., Tycko B. Epigenetic lesions at the H19 locus in Wilms' tumor patients. Nat. Genet. 1994, 7:440-447.
9. Yoshimizu T., Miroglio A., Ripoche M.A., Gabory A., Vernucci M., Riccio A., Colnot S., Godard C., Terris B., Jammes H., Dandolo L. The H19 locus acts in vivo as a tumor suppressor. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12417-12422.
10. Ariel I., Lustig O., Schneider T., Pizov G., Sappir M., De-Groot N., Hochberg A. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995, 45:335-338.
11. Elkin M., Shevelev A., Schulze E., Tyckocinsky M., Cooper M., Ariel I., Pode D., Kopf E., de Groot N., Hochberg A. The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett. 1995, 374:57-61.
12. Kondo M., Suzuki H., Ueda R., Osada H., Takagi K., Takahashi T. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancer. Oncogene 1995, 10:1193-1198.
13. Hibi K., Nakamura H., Hirai A., Fujikake Y., Kasai Y., Akiyama S., Ito K., Takagi H. Loss of H19 imprinting in esophageal cancer. Cancer Res. 1996, 65:480-482.
14. Lustig-Yariv O., Schulze E., Komitowski D., Erdmann V., Schneider T., de Groot N., Hochberg A. The expression of the imprinted H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?. Oncogene 1997, 15:169-177.
15. Matouk I.J., Ohana P., Galun E., Hochberg A. The pivotal role of the oncofetal H19 RNA in human cancer, a new hope. Gene Therapy and Cancer Research Focus 2008, 241-260. Nova publisher.
16. Ayesh S., Matouk I., Schneider T., Ohana P., Laster M., de Groot N., Hochberg A. Possible physiological role of H19 RNA. Mol. Carcinog. 2002, 35:63-74.
17. Barsyte-Lovejoy D., Lau S.K., Boutros P.C., Khosravi F., Jurisica I., Andrulis I.L., Tsao M.S., Penn L.Z. The c-Myc oncogene directly induces the H19 non-coding RNA by allele specific binding to potentiate tumorigenesis. Cancer Res. 2006, 66:5330-5337.
18. Berteaux N., Lottin S., Monte D., Pinte S., Quatannens B., Coll J., Hondermarck H., Curgy J.J., Dugimont T., Adriaenssens E. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J. Biol. Chem. 2005, 280. 29625-29636.
19. Smits G., Mungall A.J., Griffiths-Jones S., Smith P., Beury D., Matthews L., Rogers J., Pask A.J., Shaw G., VandeBerg J.L., McCarrey J.R., Renfree M.B., Reik W., Dunham I. Conservation of H19 non-coding RNA and H19-IGF2 imprinting mechanism in therians. Nat. Genet. 2008, 40:971-976.
20. Singh V., Srivastava M. Enhancer blocking activity of the insulator at H19-ICR is independent of chromatin barrier. Mol. Cell. Biol. 2008, 28:3767-3775.
21. Matouk I., Ohana P., Ayesh S., Sidi A., Czerniak A., de Groot N., Hochberg A. The oncofetal H19 RNA in human cacer, from the bench to the patient. Cancer Therapy. 2005, 3:249-266.
22. Dugimont T., Montpellier C., Adriaenssens E., Lottin S., Dumont L., Iotsova V., Lagrou C., Stéhelin D., Coll J., Curgy J.J. The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53. Oncogene 1998, 16:2395-2401.
23. Oda S., Oda T., Nishi K., Takabuchi S., Wakamatsu T., Adachi T., Fukuda K., Semenza G.L., Hirota K. Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS ONE 2008, 3:e2215.
24. Murray-Zmijewski F., Slee E.A., Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat. Rev. Mol. Cell. Biol. 2008, 9:702-712.
25. Koumenis C., Alarcon R., Hammond E., Sutphin P., Hoffman W., Murphy M., Derr J., Taya Y., Lowe S.W., Kastan M., Giaccia A. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell. Biol. 2001, 4:1297-1310.
26. Fernandez-Fernandez M.R., Veprintsev D.B., Fersht A.R. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc. Natl. Acad. Sci. USA 2005, 102:4735-4740.
27. Baptiste N., Prives C. P53 in the cytoplasm. A question of overkill?. Cell 2004, 116:487-489.
28. Li Y.M., Franklin G., Cui H.M., Svensoon K., He X.B., Adam G., Ohlsson R., Pfeifer S. The H19 transcript is associated with polysomes and may regulate IGF2 expression in trans. J. Biol. Chem. 1998, 273:28247-28252.
29. Boyd S.D., Tsai K.Y., Jacks T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2000, 2:563-568.
30. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 1999, 18:1660-1672.
31. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000, 14:34-44.
32. Blagosklonny M.V., An W.G., Romanova L.Y., Trepel J., Fojo T., Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 1998, 273:11995-11998.
33. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996, 379:88-91.
34. Schmaltz C., Hardenbergh P.H., Wells A., Fisher D.E. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol. Cell. Biol. 1998, 18:2845-2854.
35. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia inducible factor 1 α in common human cancers and their metastases. Cancer Res. 1999, 59. 5830-5835.